Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
about
Current use of phosphodiesterase inhibitors in urologyAvanafil for male erectile dysfunction: a systematic review and meta-analysis.Future prospects in the treatment of erectile dysfunction: focus on avanafil.Avanafil for erectile dysfunction.Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.ADMET considerations for phosphodiesterase-5 inhibitors.Avanafil for treatment of erectile dysfunction: review of its potential.PDE5 inhibitors: considerations for preference and long-term adherence.Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.The Challenge of Erectile Dysfunction Management in the Young Man.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Avanafil - a further step to tailoring patient needs and expectations.Avanafil for the treatment of erectile dysfunction.Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact.Time of onset of vardenafil orodispersible tablet in a real-life setting - looking beyond randomized clinical trials.Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers.Intracellular calcium concentration of corpus cavernosum smooth muscle cells is decreased by the overexpression of PnNOS gene in adipose tissue-derived stem cells.Crystal engineering of multiple-component organic solids: Pharmaceutical cocrystals of tadalafil with persistent hydrogen bonding motifs
P2860
Q26795512-6F595FBE-061B-4158-AD99-B354DAFD0660Q33621456-706D6ADA-CB15-4966-9787-869E48DD2D32Q34029414-1FA4169C-4FC2-49E6-9A30-15FAD9DF1064Q34039001-BE7F8ED5-8D21-4524-BC48-A8124A901E2AQ37180996-B9DFE31F-91F7-4B6F-9742-B0CA9D9DCCEDQ38024409-F06DC2BB-1BEC-4034-A536-750D9A288057Q38042912-666FE102-1127-418D-B3AC-B489B6BA0059Q38122721-68277A5D-A198-42DA-8F08-553166F22A96Q38248275-C8859A85-C57F-49AE-8459-8589DDE638D1Q38464139-8053849A-FE9E-4F84-ADCD-7193A3049B0DQ38631968-84D5ED87-0EC7-4E37-883D-55F9662344E4Q38815890-A344ABFF-FDDD-4020-AE71-AB50A56B111BQ38846047-0001BD13-E056-4140-BD36-53CEBD0CA420Q38896836-72CE56C7-62C8-4C41-B7DC-8F0C345FFCB1Q38966016-4DAD97C3-BBB8-4081-BBF0-F3F2A719E59FQ38994942-6A7CBF4F-7F8F-480B-B003-88A6644EA229Q41862014-E5BDC98A-7B46-4287-A286-A1C436E72830Q45868580-9241C021-10F1-4A36-A4CA-F816D47F436DQ57834025-1C195077-E7F4-4E13-BE64-EC72AC49F88A
P2860
Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@ast
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@en
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@nl
type
label
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@ast
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@en
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@nl
prefLabel
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@ast
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@en
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@nl
P2093
P2860
P1476
Avanafil, a new rapid-onset ph ...... tment of erectile dysfunction.
@en
P2093
Niels Johnsen
Wayne J G Hellstrom
P2860
P304
P356
10.1517/13543784.2010.518955
P407
P577
2010-10-13T00:00:00Z